Show simple item record

dc.contributor.authorNordestgaard BG
dc.contributor.authorLangsted A
dc.contributor.authorMora S
dc.contributor.authorKolovou G
dc.contributor.authorBaum H
dc.contributor.authorBruckert E
dc.contributor.authorWatts GF
dc.contributor.authorSypniewska G
dc.contributor.authorWiklund O
dc.contributor.authorBorén J
dc.contributor.authorChapman MJ
dc.contributor.authorCobbaert C
dc.contributor.authorDescamps OS
dc.contributor.authorvon Eckardstein A
dc.contributor.authorKamstrup PR
dc.contributor.authorPulkki K
dc.contributor.authorKronenberg F
dc.contributor.authorRemaley AT
dc.contributor.authorRifai N
dc.contributor.authorRos E et al
dc.date.accessioned2018-02-26T13:22:43Z
dc.date.available2018-02-26T13:22:43Z
dc.date.issued2016
dc.identifier.urihttps://erepo.uef.fi/handle/123456789/6168
dc.description.abstractAims To critically evaluate the clinical implications of the use of non-fasting rather than fasting lipid profiles and to provide guidance for the laboratory reporting of abnormal non-fasting or fasting lipid profiles. Methods and results Extensive observational data, in which random non-fasting lipid profiles have been compared with those determined under fasting conditions, indicate that the maximal mean changes at 1–6 h after habitual meals are not clinically significant [+0.3 mmol/L (26 mg/dL) for triglycerides; −0.2 mmol/L (8 mg/dL) for total cholesterol; −0.2 mmol/L (8 mg/dL) for LDL cholesterol; +0.2 mmol/L (8 mg/dL) for calculated remnant cholesterol; −0.2 mmol/L (8 mg/dL) for calculated non-HDL cholesterol]; concentrations of HDL cholesterol, apolipoprotein A1, apolipoprotein B, and lipoprotein(a) are not affected by fasting/non-fasting status. In addition, non-fasting and fasting concentrations vary similarly over time and are comparable in the prediction of cardiovascular disease. To improve patient compliance with lipid testing, we therefore recommend the routine use of non-fasting lipid profiles, while fasting sampling may be considered when non-fasting triglycerides >5 mmol/L (440 mg/dL). For non-fasting samples, laboratory reports should flag abnormal concentrations as triglycerides ≥2 mmol/L (175 mg/dL), total cholesterol ≥5 mmol/L (190 mg/dL), LDL cholesterol ≥3 mmol/L (115 mg/dL), calculated remnant cholesterol ≥0.9 mmol/L (35 mg/dL), calculated non-HDL cholesterol ≥3.9 mmol/L (150 mg/dL), HDL cholesterol ≤1 mmol/L (40 mg/dL), apolipoprotein A1 ≤1.25 g/L (125 mg/dL), apolipoprotein B ≥1.0 g/L (100 mg/dL), and lipoprotein(a) ≥50 mg/dL (80th percentile); for fasting samples, abnormal concentrations correspond to triglycerides ≥1.7 mmol/L (150 mg/dL). Life-threatening concentrations require separate referral when triglycerides >10 mmol/L (880 mg/dL) for the risk of pancreatitis, LDL cholesterol >13 mmol/L (500 mg/dL) for homozygous familial hypercholesterolaemia, LDL cholesterol >5 mmol/L (190 mg/dL) for heterozygous familial hypercholesterolaemia, and lipoprotein(a) >150 mg/dL (99th percentile) for very high cardiovascular risk. Conclusion We recommend that non-fasting blood samples be routinely used for the assessment of plasma lipid profiles. Laboratory reports should flag abnormal values on the basis of desirable concentration cut-points. Non-fasting and fasting measurements should be complementary but not mutually exclusive.en
dc.language.isoENen
dc.publisherOxford University Press (OUP)en
dc.relation.ispartofseriesEUROPEAN HEART JOURNALen
dc.relation.urihttp://dx.doi.org/10.1093/eurheartj/ehw152en
dc.rightsCC BY-NC http://creativecommons.org/licenses/by-nc/4.0/en
dc.subjectlipidsen
dc.subjectlipoproteinsen
dc.subjectcardiovascular diseaseen
dc.subjectstrokeen
dc.subjectreference valuesen
dc.subjectnormal valuesen
dc.titleFasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicineen
dc.description.versionpublished versionen
dc.contributor.departmentSchool of Medicine / Clinical Medicineen
uef.solecris.id44106251en
dc.type.publicationinfo:eu-repo/semantics/articleen
dc.rights.accessrights© Authorsen
dc.relation.doi10.1093/eurheartj/ehw152en
dc.description.reviewstatuspeerRevieweden
dc.format.pagerange1944 -1958en
dc.relation.issn0195-668Xen
dc.relation.issue25en
dc.relation.volume37en
dc.rights.accesslevelopenAccessen
dc.type.okmA1en
dc.type.versioninfo:eu-repo/semantics/publishedVersionen
uef.solecris.openaccessHybridijulkaisukanavassa ilmestynyt avoin julkaisu


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record